CATEGORIES: Research
Rare Neurological Disease Special Report

HNF Featured in Rare Neurological Disease Special Report

by | Apr 9, 2019 | 0 comments

rare neurological disease special report

The Hereditary Neuropathy Foundation is proud to announce that for the fifth year in a row, we have been featured in the annual Rare Neurological Disease Special Report—a widely-read supplement included in the mailing of the March issues of Neurology Reviews. It is also distributed at all major neurology conferences throughout the year, including the 2019 MDA Clinical and Scientific Conference in Orlando, Florida April 13th-17th. If you attend come visit HNF at the Neurology Reviews booth.

We are diligently educating neurologists and Health Care Providers about CMT on your behalf.

Neurology Reviews is the first and original news source in neurology and has a history of providing independent, unbiased news to neurologists and clinicians interested in the neurosciences.

Here is what HNF featured in the March, 2019 edition: 

  • HNF ad “What is CMT?” page 10

  • “FDA Hears the CMT Community Voice Loud and Clear on September 28, 2018” page 11

  • “CMT1A and Impaired Patient Mobility: Expressions, Remedies, and Impact of Quality of Life” page 12

  • HNF’s Industry Partners Pharnext & Acceleron page 35 & 36

  • HNF’s Research Partner Dr. Stephen Züchner page 38-41

  • PSA Genetic Testing Awareness for Neurologists page 80

As with all of HNF’s programs, we rely on donations and support from our industry sponsors, government grants and YOU! Please donate today to support our continued medical outreach initiatives.

Learn more on this topic

Related Blog Posts

A New Mouse Model for Charcot-Marie-Tooth (CMT2)

We were recently informed that The Jackson Laboratory (JAX, a nonprofit biomedical research institution headquartered in Bar Harbor, Maine) had taken delivery and will be distributing a newly generated CMT-related mouse model. The new model expresses mutant mitofusin 2, a mitochondrial membrane protein involved in mitochondrial fusion and regulation of vascular smooth muscle cell proliferation.

Hot Off the Press – Potential Treatment for CMT1A

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

Support CMT Therapeutic Alliance

HNF has entered into a joint venture – the CMT Therapeutic Alliance – with a unique non profit organization (BioPontis Alliance for Rare Diseases) that brings professional drug discovery capabilities to translate our research results into potential treatments.

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news